JMP Analyst Names 5 Gambling Stocks To Buy On The Dip
It's been a rough year so far for casino and online gambling stocks, but one firm has identified a handful of gambling stocks that investors should consider buying on the dip. The Analyst: JMP Securities analyst Jordan Bender has initiated coverage of the ...
Benzinga · 2h ago
J.P. Morgan Sees an ‘Attractive Entry Point’ in These 2 Stocks
Did markets hit a turning point? The past couple of months brought us a seven-week losing streak in stocks, the longest such streak in over a decade, but the week before the Memorial Day holiday weekend saw strong gains. The S&P 500 wiped out its May losse...
TipRanks · 06/01 15:02
Is Penumbra, Inc. (NYSE:PEN) Popular Amongst Insiders?
If you want to know who really controls Penumbra, Inc. ( NYSE:PEN ), then you'll have to look at the makeup of its...
Simply Wall St. · 05/12 17:28
Penumbra's Return on Invested Capital Insights
Pulled from Benzinga Pro data, Penumbra (NYSE:PEN) posted Q1 earnings of $79.00 thousand, an increase from Q4 of 100.32%. Sales dropped to $203.90 million, a 0.06% decrease between quarters.
Benzinga · 05/12 14:16
Despite Seeing Accelerated 2023 Growth, This Analyst Cut Penumbra's Price Target - Here's Why
Benzinga · 05/04 19:54
What 4 Analyst Ratings Have To Say About Penumbra
Analysts have provided the following ratings for Penumbra (NYSE:PEN) within the last quarter:
Benzinga · 05/04 13:21
--Wells Fargo Adjusts Penumbra's Price Target to $265 from $321, Keeps Overweight Rating
MT Newswires · 05/04 12:24
Penumbra (PEN) Reports Q1 Loss, Tops Revenue Estimates
Penumbra (PEN) delivered earnings and revenue surprises of -116.67% and 4.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/03 22:15
Penumbra: Q1 Earnings Insights
Penumbra (NYSE:PEN) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Penumbra missed estimated earnings by 116.67%, reporting an EPS of $-0.01 versus an estimate of $0...
Benzinga · 05/03 21:41
Penumbra Q1 GAAP EPS $0.00 vs $0.32 In Same Qtr. Last Year, Adj. Net Loss $2.261M vs Net Income $13.463M In Same Qtr. Last Year, Sales $203.90M Beat $195.04M Estimate
Penumbra (NYSE:PEN) reported quarterly sales of $203.90 million which beat the analyst consensus estimate of $195.04 million by 4.54 percent. This is a 20.51 percent increase over sales of $169.20 million the same
Benzinga · 05/03 20:57
Penumbra Non-GAAP EPS of -$0.01 misses by $0.05, revenue of $203.9M beats by $8.51M
Penumbra press release (NYSE:PEN): Q1 Non-GAAP EPS of -$0.01 misses by $0.05. Revenue of $203.9M (+20.5% Y/Y) beats by $8.51M.
Seekingalpha · 05/03 20:23
Penumbra Swings to Q1 Non-GAAP Loss; Revenue Rises
MT Newswires · 05/03 16:47
-- Earnings Flash (PEN) PENUMBRA Posts Q1 Revenue $203.9M, vs. Street Est of $195.4M
MT Newswires · 05/03 16:25
-- Earnings Flash (PEN) PENUMBRA Reports Q1 Loss $-0.01, vs. Street Est of $0.04
MT Newswires · 05/03 16:17
Earnings Reaction History: PENUMBRA INC, 66.7% Follow-Through Indicator, 5.0% Sensitive
MT Newswires · 05/03 12:30
Penumbra Q1 2022 Earnings Preview
Penumbra (NYSE:PEN) is scheduled to announce Q1 earnings results on Tuesday, May 3rd, after market close. The consensus EPS Estimate is $0.04 (-85.2% Y/Y) and the consensus Revenue Estimate is
Seekingalpha · 05/02 21:45
Notable earnings after Tuesday's close
Seekingalpha · 05/02 21:35
Penumbra, Inc. to Present at the Bank of America Securities 2022 Healthcare Conference
Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10, 2022.
PR Newswire · 04/26 20:05
Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 04/26 19:01
Deutsche Bank Initiates Coverage on Penumbra With Buy Rating, $250 Price Target
MT Newswires · 04/19 08:13
Webull provides a variety of real-time PEN stock news. You can receive the latest news about Penumbra Inc through multiple platforms. This information may help you make smarter investment decisions.
About PEN
Penumbra, Inc. is a global healthcare company. The Company is engaged in the design, development, manufacturing, and marketing of medical devices. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization and access technologies. The Company's neuro products include Thrombectomy, Embolization, Neurovascular access, Neurosurgical Tools, and Virtual Reality Platform. Its Vascular products include Thrombectomy and Embolization. The principal specialist physicians and healthcare providers in its two target end markets include Neuro: Interventional neuroradiologists, neurosurgeons, interventional neurologists, occupational therapists, physical therapists, and physiatrists; Vascular: Interventional radiologists, vascular surgeons, and interventional cardiologists. The common vascular and neurovascular diseases the Company focuses on are Ischemic Stroke, Brain Aneurysm, Hemorrhagic Stroke, Venous Thromboembolism, and Acute Coronary Syndrome.